Semaglutide in Patients with Diabetic Eye Disease and Type 2 Diabetes (FOCUS)

In by ECIR

Semaglutide in Patients with Diabetic Eye Disease and Type 2 Diabetes (FOCUS)

  • This field is for validation purposes and should be left unchanged.

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (FOCUS)

clinicaltrials.gov

Eligibility

Inclusion Criteria

• Male or female > 18 years old
• Diagnosed with type 2 diabetes mellitus grat least 10 years
• HbA1c of 7.0-10.0%

Exclusion Criteria

• Any of the following: myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within the past 60 days prior to the day of screening
• Planned coronary, carotid or peripheral artery revascularisation
• New York Heart Association (NYHA) Class IV
• Renal impairment measured eGFR less than 30 ml/min/1.73 m^2

Back to Current Studies